Pay My Bill
Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) is an intestinal disorder that causes abdominal pain or discomfort, cramping or bloating, and diarrhea or constipation. Irritable bowel syndrome is a long-term but manageable condition. IBS is one of the most common intestinal disorders. Most people's symptoms are so mild that they never see a doctor for treatment. However, some people may have troublesome symptoms, especially abdominal cramps, bloating, and diarrhea. The cause of irritable bowel syndrome is not well understood. In IBS, the movement of the digestive tract is impaired, but doctors can find no change in physical structure, such as inflammation or tumors.
Treatment will depend on the types of symptoms you have and their severity, as well as how they affect your daily life, and will likely involve changes to your lifestyle. Active involvement in treatment is important to managing it successfully. Treatment usually focuses on changes in diet and lifestyle, avoiding certain trigger foods and managing stress.
Investigators L. Berardi, De Amici, M. Castello, C. Torre, Giunta, Legoratto, and Vignini studied 48 patients who participated in an elimination diet based on ALCAT results. They found that the ALCAT-based diet improved symptoms in 71% of patients. In particular, symptom improvements were most evident in patients with higher symptom scores, dietary changes and everyday conditions. Presented at 30th Congress of the European Academy of Allergy and Clinical Immunology, 11-15 June 2011 - Istanbul, Turkey, and published in Allergy Volume 66, Supplement s94, June 2011 – pg. 63, abstract 552.
Investigators Berardi, De Amici, Vignini, Mantegna, and Mosca conducted a study with a group of 15 patients (4 males and 11 females) affected by GI symptoms and negative for allergies (prick and/or rast); the participants agreed to be tested with the ALCAT test. They concluded that 54% of the test subjects’ symptoms improved significantly. Presented at 28th Congress of the European Academy of Allergy and Clinical Immunology, 6-10 June 2009 – Warsaw, Poland, and published in Allergy Volume 64, Supplement 90, 2009 – pg. 490, abstract 1280.
Investigator Douglas H. Sandberg MD closely monitored three patients, which demonstrated that an ALCAT Based elimination plan coupled with titration skin testing was an effective method in alleviating symptoms of gastrointestinal disorders. Published in International Pediatrics Volume 5, Number 1, 1990
Investigators Peter J. Fell MD, Sally Soulsby SRN, and Jonathan Brostoff MD DM conducted a double blind, placebo controlled study on 20 patients which demonstrated that an ALCAT based elimination diet dramatically improved symptoms of IBS and had a statistically significant correlation between an ALCAT score and symptom provocation. Published in Journal of Nutritional Medicine, Volume 2, Number 2, 1991.
Investigator Danuta Mylek studied 72 patients who followed an ALCAT based elimination diet; they had significant improvement in their symptoms that included arthritis, bronchitis and gastro issues. Specifically, they found improvement in 83% of arthritis patients, 75% of Urticaria, bronchitis, and gastroenteritis patients, 70% of migraine patients, 60% of chronic fatigue syndrome patients, 50% of asthma patients, 49% of AD patients, 47% of rhinitis patients and 32% of hyperactivity patients. Patients were also skin tested for IgE allergy to inhalants and foods that were more pronounced in skin and nasal symptoms. Published in Advances in Medical Sciences; Formerly Roczniki Akademii Medycznej w Białymstoku Volume 40, Number 3, 1995.
Investigator Barbara A. Solomon MD studied 172 patients successfully using an ALCAT Test-based diet to alleviate the following range of symptoms: classic migraine (85%), common migraine (62%), sinus headaches (58%), gastoesphageal reflux (GERD) (75%), IBS (71%), inflammatory arthritis (65%), recurrent Sinusitis (59%), tension fatigue, syndrome (60%), obesity (50%), eczema (55%), asthma (30%), depression and/or anxiety (31%), recurrent vaginitis (20%), recurrent urinary tract infection (46%), degenerative arthritis (44%) and allergic rhinitis (42%). Published in Environmental Medicine, Volume 9, Number 1 & 2, 1992. Barbara Solomon MD, MA
Dr. Mara De Amici, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy